Clinical trial · Interventional
Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints
Comparative Study Evaluating Clinical Outcomes for Patients Treated With Tocilizumab for Sever COVID-19 Infection in Breast Cancer Patients Versus Non Cancer Patients
NCT04871854CI-TRIAL-00061836completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare evaluating Clinical outcomes for patients treated with with or without breast cancer patients comorbidity for sever COVID-19 infection in breast cancer patients versus non cancer patients and evaluating Tocilizumab efficacy versus traditional therapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tocilizumab | Drug | — | UNRESOLVED |
| traditional Covid -19 therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Svere infected Covid-19 control
- description
- Arm one confirmed sever COVID 19 infection admitted to ICU including with or without breast cancer patients comorbidity receive traditional therapy
- interventionNames
- Drug: traditional Covid -19 therapy
- type
- ACTIVE_COMPARATOR
- label
- sever infected Covid -19 pateints study
- description
- Arm two patients with confirmed sever COVID 19 infection admitted to ICU with or without breast cancer patients comorbidity tocilizumab
- interventionNames
- Drug: Tocilizumab
Primary outcomes (3)
- measure
- Overall survival (OS) after treatment of Tocilizumab
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. patients admitted to ICU with or without breast cancer (non-metastatic) comorbidity 2. age 18-85 years' old 3. moderate to sever confirmed COVID 19 infection through PCR and CT 4. male or female 5. confirmed Covid-19 by PCR 6. Requiring ICU admission 7. WITH evidence of severe COVID-19 (at least 2 of the following): 1. Fever \> 38C within 72 hours 2. Pulmonary infiltrate on chest X ray /ground glass opacity 3. Need for supplemental O2 to maintain saturation \> 92% 8. AND at least 1 of the following: 1. Ferritin \> 500 ng/ml 2. CRP \> 50 mg/L 3. LDH \>250 U/L 4. D-dimer \> 1000 ng/mL 9. all patient assigned informed consent Exclusion Criteria: 1. above 85 years' old 2. metatastic breast cancer 3. autoimmune disease patients 4. Unable to provide verbal informed consent 5. preganncy 6. Subjects between the ages of 70 and 75 will be excluded if they have NYHA Class III/IV heart failure 7. Active TB 8. Receipt of IV tocilizumab for the treatment of a non-COVID condition within 3 weeks of the first COVID symptom 9. History of hypersensitivity to tocilizumab 7. ANC \<500, Platelets \<50,000\* 8. AST/ALT \> 5X ULN
References
Publications (0)
Data not yet available
No reference posted for this study.